Literature DB >> 15940251

Nfkb 1 is dispensable for Myc-induced lymphomagenesis.

Ulrich Keller1, Jonas A Nilsson, Kirsteen H Maclean, Jennifer B Old, John L Cleveland.   

Abstract

Rel/NF-kappaB transcription factors are critical arbiters of immune responses, cell survival, and transformation, and are frequently deregulated in cancer. The p50 NF-kappaB 1 component of Rel/NF-kappaB DNA-binding dimers regulates genes involved in both cell cycle traverse and apoptosis. Nfkb 1 loss accelerates B cell growth and leads to increased B cell turnover in vivo, phenotypes akin to those manifested in B cells of Emu-Myc transgenic mice, a model of human Burkitt lymphoma. Interestingly, Emu-Myc B cells express reduced levels of cytoplasmic and nuclear NF-kappaB 1 and have reduced Rel/NF-kappaB DNA-binding activity, suggesting that Myc-mediated repression of NF-kappaB 1 might mediate its proliferative and apoptotic effects on B cells. Furthermore, Nfkb 1 expression was reduced in the majority of Emu-Myc lymphomas and was also suppressed in human Burkitt lymphoma. Nonetheless, loss of Nfkb 1 did not appreciably affect Myc's proliferative or apoptotic responses in B cells and had no effect on lymphoma development in Emu-Myc mice. Therefore, Nfkb 1 is dispensable for Myc-induced lymphomagenesis.. Oncogene (2005) 24, 6231-6240

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15940251     DOI: 10.1038/sj.onc.1208779

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

Review 1.  c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.

Authors:  Chenguang Wang; Yanhong Tai; Michael P Lisanti; D Joshua Liao
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

2.  HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling.

Authors:  Roland Walter; Kuan-Ting Pan; Carmen Doebele; Federico Comoglio; Katarzyna Tomska; Hanibal Bohnenberger; Ryan M Young; Laura Jacobs; Ulrich Keller; Halvard Bönig; Michael Engelke; Andreas Rosenwald; Henning Urlaub; Louis M Staudt; Hubert Serve; Thorsten Zenz; Thomas Oellerich
Journal:  Blood       Date:  2016-11-15       Impact factor: 22.113

3.  Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.

Authors:  Alexander Hoellein; Mohammad Fallahi; Stephanie Schoeffmann; Sabine Steidle; Franz X Schaub; Martina Rudelius; Iina Laitinen; Lisa Nilsson; Andrei Goga; Christian Peschel; Jonas A Nilsson; John L Cleveland; Ulrich Keller
Journal:  Blood       Date:  2014-08-20       Impact factor: 22.113

4.  Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival.

Authors:  Jasmin Corso; Kuan-Ting Pan; Roland Walter; Carmen Doebele; Sebastian Mohr; Hanibal Bohnenberger; Philipp Ströbel; Christof Lenz; Mikolaj Slabicki; Jennifer Hüllein; Federico Comoglio; Michael A Rieger; Thorsten Zenz; Jürgen Wienands; Michael Engelke; Hubert Serve; Henning Urlaub; Thomas Oellerich
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-06       Impact factor: 11.205

5.  Bptf determines oncogenic addiction in aggressive B-cell lymphomas.

Authors:  Irene Felipe; Pilar Delgado; Laia Richart; Mónica P de Andrés; Jaime Prieto; Natalia Del Pozo; Juan F García; Miguel A Piris; Almudena Ramiro; Francisco X Real
Journal:  Oncogene       Date:  2020-05-25       Impact factor: 9.867

6.  Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma.

Authors:  Seiichi Mori; Rachel E Rempel; Jeffrey T Chang; Guang Yao; Anand S Lagoo; Anil Potti; Andrea Bild; Joseph R Nevins
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

7.  BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells.

Authors:  S V Muralidharan; J Bhadury; L M Nilsson; L C Green; K G McLure; J A Nilsson
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

8.  Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.

Authors:  W-J Chng; G F Huang; T H Chung; S B Ng; N Gonzalez-Paz; T Troska-Price; G Mulligan; M Chesi; P L Bergsagel; R Fonseca
Journal:  Leukemia       Date:  2011-04-05       Impact factor: 11.528

9.  Myc suppression of Nfkb2 accelerates lymphomagenesis.

Authors:  Ulrich Keller; Jürgen Huber; Jonas A Nilsson; Mohammad Fallahi; Mark A Hall; Christian Peschel; John L Cleveland
Journal:  BMC Cancer       Date:  2010-07-02       Impact factor: 4.430

10.  Cyclin D1 inhibits whereas c-Myc enhances the cytotoxicity of cisplatin in mouse pancreatic cancer cells via regulation of several members of the NF-κB and Bcl-2 families.

Authors:  Ayman El-Kady; Yuan Sun; Ying-Xia Li; D Joshua Liao
Journal:  J Carcinog       Date:  2011-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.